<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051124</url>
  </required_header>
  <id_info>
    <org_study_id>20-01579</org_study_id>
    <secondary_id>1R56HL150036</secondary_id>
    <nct_id>NCT05051124</nct_id>
  </id_info>
  <brief_title>Peers and Technology for Adherence, Access, Accountability, and Analytics</brief_title>
  <acronym>PT4A</acronym>
  <official_title>PT4A (Peers and Technology for Adherence, Access, Accountability, and Analytics) - A Qualitative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this project is to utilize the PRECEDE-PROCEED framework to conduct&#xD;
      transdisciplinary, translational implementation research focused on improving medication&#xD;
      adherence for hypertension control. The central hypothesis is that peer delivery of&#xD;
      medications integrated with HIT (PT4A) will be effective in improving hypertension medication&#xD;
      adherence, contributing to improved blood pressure among patients with uncontrolled&#xD;
      hypertension in western Kenya. This application will focus on the critical formative&#xD;
      components of the overall implementation research objective. This study record will focus on&#xD;
      Sub-Aim 2.2: a pilot of the intervention and focus group discussions with patients, peers,&#xD;
      and clinical staff will be conducted to evaluate feasibility. The study team will also&#xD;
      evaluate impact on systolic blood pressure, medication adherence, and fidelity of&#xD;
      implementation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Mean Change in Systolic Blood Pressure (SBP)</measure>
    <time_frame>Baseline, Month 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pill count adherence ratio</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Proportion of prescribed doses taken over a 1-month time period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of confirmed medication deliveries</measure>
    <time_frame>Month 3</time_frame>
    <description>Confirmed medication delivery will be documented by patient e-signature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of peer completions of the HIT form</measure>
    <time_frame>Month 3</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Hypertension</condition>
  <condition>Medication Adherence</condition>
  <arm_group>
    <arm_group_label>Sub-Aim 2.2 Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Peer Delivery of Medications</intervention_name>
    <description>The study team will adopt a novel approach of extending beyond the use of peer support in the clinical setting and implement door-to-door peer delivery of medications within patients' communities</description>
    <arm_group_label>Sub-Aim 2.2 Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Health Information Technology (HIT) Platform</intervention_name>
    <description>To support peer delivery, the study team will use a HIT platform that performs 4 core functions: 1) tailored counseling strategies through decision support; 2) teleconsultation support for clinician-peer-patient interactions; 3) tracking medication refills to enhance accountability of the peer delivery process; and 4) analytics to improve medication supply chain by generating patient-level drug consumption data. This is an innovative use of HIT to accomplish these functions to support medication adherence.</description>
    <arm_group_label>Sub-Aim 2.2 Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients ≥ 18 years old&#xD;
&#xD;
          -  Enrolled in the AMPATH CDM PRogram&#xD;
&#xD;
          -  Have uncontrolled hypertension (defined as systolic blood pressures ≥ 140 or diastolic&#xD;
             blood pressure ≥ 90)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute illness requiring immediate medical attention&#xD;
&#xD;
          -  Terminal illness&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajesh Vedanthan, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajesh Vedanthan, MD, MPH</last_name>
    <phone>646-501-3890</phone>
    <email>rajesh.vedanthan@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julia Dickhaus</last_name>
    <phone>646-501-3663</phone>
    <email>julia.dickhaus@nyulangone.org</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 10, 2021</study_first_submitted>
  <study_first_submitted_qc>September 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>Investigators whose proposed use of the data has been approved by an independent review committee (&quot;learned intermediary&quot;) identified for this purpose will have access to the data upon reasonable request. Requests should be directed to rajesh.vedanthan@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

